R.PR
REGISTERED-PRINCIPAL REGISTER
14/07/2020
Voltar para busca
Dado oficial do USPTO
NANOGENICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
14/07/2020
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
09/08/2018
Data de registro
14/07/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/07/2020
Última transação
14/07/2020
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
COLLOPY, DIANE PATRICIA
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Nanogenics Limited
Representantes
Thomas W. Cole ROBERTS MLOTKOWSKI SAFRAN COLE & CALDERON P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderscystic fibrosisglaucomaeye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations containing siRNARNAshRNAmRNA or DNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseasesimmune system-related diseases and disordersdiseases of the brain; pharmaceutical medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing siRNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing shRNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing mRNA for treatments in the form of gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing DNA for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations containing lipidsliposomes or peptides for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations being pharmaceuticals containing lipidsliposomes or peptides for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; medical preparations for use in gene therapy for the treatment of tumours; biochemical preparations for medical purposes for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; biological preparations for medical purposes for use in relation to gene therapy for the treatment of cancerrespiratory diseases and disorderseye diseasesbone diseasesvascular diseasesliver diseaseimmune system-related diseases and disordersdiseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations being nanoparticles for the treatment of cancer; pharmaceutical preparations containing siRNARNAshRNAmRNA or DNA for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals ; drug delivery agents being made from lipidsliposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations in the form of nanoparticles; drug delivery agents for use in relation to the delivery of siRNAshRNAmRNARNADNA or other genetic material in the form of nanoparticles; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; none of the aforesaid for use in relation to the treatment of hair loss or hair growth stimulation
Classe 42
Medical and pharmacological research services all in the field of gene therapy and treatment of cancer; biological researchclinical research and medical research all in the field of gene therapy; research in the field of gene therapy; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical product development; research of pharmaceuticals; research relating to pharmaceutical delivery agents; development of pharmaceutical delivery agents; research and development in the pharmaceutical and biotechnology fields; providing information about the results of clinical trials for pharmaceutical products; scientific research services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and substances; development of pharmaceuticals and pharmaceutical preparations being nanoparticles; development of pharmaceuticals and pharmaceutical preparations containing siRNARNAshRNAmRNA or DNA; development of drug delivery agents being made from lipidsliposomes or peptides; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations; development of pharmaceutical and drug delivery agents for use in relation to the delivery of siRNAshRNAmRNARNADNA or other genetic material; development of pharmaceuticals and pharmaceutical preparations for use in gene therapy; development of drug delivery agents for use in gene therapy; development of drug delivery agents being nanoparticles; providing consulting to medical research companies in the design and conduct of clinical trials and proving consulting to pharmaceutical companies in the design of pharmaceutical products
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
10/06/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/06/2020
IUCN
NOTICE OF ALLOWANCE CANCELLED
29/04/2020
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
29/04/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
28/04/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/04/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
28/04/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
21/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/02/2020
PUBO
PUBLISHED FOR OPPOSITION
25/02/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
30/06/2019
GNRT
NON-FINAL ACTION E-MAILED
30/06/2019
CNRT
NON-FINAL ACTION WRITTEN
30/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/06/2019
ALIE
ASSIGNED TO LIE
30/05/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/05/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
25/11/2018
GNRT
NON-FINAL ACTION E-MAILED
25/11/2018
CNRT
NON-FINAL ACTION WRITTEN
25/11/2018
DOCK
ASSIGNED TO EXAMINER
15/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/08/2018
NWAP
NEW APPLICATION ENTERED
13/08/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NANOGENICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.